Business Description
Cantargia AB
ISIN : SE0006371126
Total Employee Number:
22Compare
Compare
Traded in other countries / regions
CANTA.Sweden7V3.GermanyCANTAs.UK IPO Date
2019-09-02Description
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.53 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.12 | |||||
Interest Coverage | 9.56 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 5.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | -22.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.09 | |||||
Quick Ratio | 8.09 | |||||
Cash Ratio | 7.88 | |||||
Days Sales Outstanding | 2.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 51.15 | |||||
Net Margin % | 50.73 | |||||
EBITDA Margin % | 56.94 | |||||
FCF Margin % | 49.68 | |||||
OCF Margin % | 49.84 | |||||
ROE % | 89.57 | |||||
ROA % | 70.9 | |||||
ROIC % | 387.72 | |||||
3-Year ROIIC % | -1640.57 | |||||
ROC (Joel Greenblatt) % | 18426.87 | |||||
ROCE % | 98.74 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.3 | |||||
PE Ratio without NRI | 3.3 | |||||
Price-to-Owner-Earnings | 3.64 | |||||
PS Ratio | 1.68 | |||||
PB Ratio | 2.28 | |||||
Price-to-Tangible-Book | 2.31 | |||||
Price-to-Free-Cash-Flow | 3.38 | |||||
Price-to-Operating-Cash-Flow | 3.37 | |||||
EV-to-EBIT | 2.69 | |||||
EV-to-EBITDA | 2.65 | |||||
EV-to-Forward-EBITDA | -1.14 | |||||
EV-to-Revenue | 1.51 | |||||
EV-to-FCF | 3.01 | |||||
Price-to-Graham-Number | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 2.31 | |||||
| Price-to-Net-Cash | 2.39 | |||||
Earnings Yield (Greenblatt) % | 37.16 | |||||
FCF Yield % | 29.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cantargia AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 317.21 | ||
| EPS (TTM) (kr) | 0.65 | ||
| Beta | 0.524 | ||
| 3-Year Sharpe Ratio | -0.79 | ||
| 3-Year Sortino Ratio | -0.78 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (kr) | - | ||
| 20-Day SMA (kr) | 4.174 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (kr) | 4.174 - 4.174 | ||
| Shares Outstanding (Mil) | 248.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cantargia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cantargia AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-25 | In 147 days | ||
| Third quarter earnings results for 2026 | 2026-11-25 | In 147 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-19 | In 49 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 49 days | ||
| General meeting for 2026 | 2026-05-21 15:00 | 4.17 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-19 15:00 | 4.17 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-19 07:00 | 4.17 (+0.00%) | ||
| Annual report for 2025 | 2026-04-17 | 4.17 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-20 15:00 | 4.17 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 07:00 | 4.17 (+0.00%) |
Show
Entries
Cantargia AB Frequently Asked Questions
What is Cantargia AB(CHIX:CANTAs)'s stock price today?
The current price of CHIX:CANTAs is kr4.17. The 52 week high of CHIX:CANTAs is kr4.17 and 52 week low is kr4.17.
When is next earnings date of Cantargia AB(CHIX:CANTAs)?
The next earnings date of Cantargia AB(CHIX:CANTAs) is 2026-08-19.
Does Cantargia AB(CHIX:CANTAs) pay dividends? If so, how much?
Cantargia AB(CHIX:CANTAs) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cantargia AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers